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Abstract
Background: Observational studies suggest there are gender based differences in the treatment of coronary artery
disease, with women receiving evidence based therapy less frequently than suggested by current guidelines. The
aim of our study was to evaluate gender based differences in the use of DES.
Methods: We analysed prospectively collected data from 100704 stent implantations in the PCI registry of the ALKK
between 2005 and 2009.
Results: The usage of DES increased from 16.0 to 43.9%. Although women had smaller vessel sizes, they received
DES less often compared to men (28.2 vs. 31.3%), with an adjusted odds ratio of 0.93 (95% confidence interval
0.89-0.97) at the age of 75, and an adjusted odds ratio of 0.89 (95% confidence interval 0.84-0.94) at the age of 80.
Conclusion: Despite having smaller vessels than men, women were treated less often with DES. These findings
apply to women above the age of 75 years. These findings support previous reports, that elderly women with
coronary artery disease are treated differently to men.
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Background
Cardiovascular disease remains the leading cause of
death in Europe and North-America [1]. Evidence-based
treatment of cardiovascular disease, according to
European and American guidelines, should not differ
between women and men, wether for stable coronary
artery disease, acute coronary syndromes or for revascu-
larisation procedures. Nevertheless, gender differences in
the treatment of cardiovascular disease is well recog-
nized, with women receiving less evidence-based care. In
acute coronary syndromes, women still receive beta-
blockers, ace-inhibitors and statins less frequently than
men [2]. Furthermore, invasive diagnosis and treatment
(by heart catheterisation and PCI), the most effective
treatment especially in high risk NSTEMI and STEMI, is
withheld from women frequently [3]. One postulated
reason for this is the higher age of women at the time of
diagnosis and treatment. Another reason is that women
are less frequently investigated for coronary disease since
the condition is still regarded as a “male” disease.
Furthermore, the presenting symptoms of women with
coronary artery disease are frequently overlooked, due to
their different and so-called “atypical” presentation [4].
Due to their on average smaller height and size,
women do have smaller coronary arteries, which may be
one reason for inferior results following revascularisation
procedures, either Percutaneous Coronary Intervention
PCI [5] or Coronary Artery Bypass Grafting [6]. Given
the substantially higher risk of restenosis in smaller vessels
[7, 8] the attraction of DES in reducing target lesion
revascularisation [9–13], should mean a higher usage of
DES in women is warranted.
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To evaluate possible gender differences, we analysed
the ALKK-PCI registry for gender differences and other
variables in the usage of Drug Eluting Stents (DES) and
Bare Metal Stents (BMS).
Materials
Data from 100704 stent implantations performed during
82304 interventions were prospectively collected in the
German ALKK-registry (Arbeitsgemeinschaft Leitende
Kardiologische Krankenhausärzte) from 1st quarter 2005
to 4th quarter 2009. In the present analysis, data from
28 centres in Germany which participated continuously
during the whole period were included. The project
started in 1992 as a prospective registry for quality control
in PTCA. The registry collects data about indication,
technical aspects, medication and hospital outcome in-
cluding in-hospital complications. Since 2002, the registry
is based on an obligatory quality control program that has
been introduced in Germany, which requires and checks
consecutive enrolment and the completeness of a core
dataset. The data were collected electronically and
transferred in anonymised form to the Institut für
Herzinfarktforschung for editing and statistical analysis.
The study is purely observational and was approved by
the ethics committee of the Landesaerztekammer
Rheinland-Pfalz. None of the authors has competing
interests concerning scope and results of the analysis.
All consecutive documented stent implantations for
ST-elevation myocardial infarction (STEMI), Non-ST-
elevation-Acute Coronary Syndrome (NSTE-ACS), or




Patients’ baseline and angiographic characteristics for
both sexes are presented as percentages and absolute
values with regard to categorical variables and compared
by Pearson chi-squared test and odds ratios with 95%-
confidence intervals. The distribution of continuous
variables is characterised by median and quartiles and
compared between genders by Wilcoxon rank-sum test.
The stent diameter and the number of stents per pro-
cedure is summarized by mean and standard deviation.
These descriptive statistics are based on the available
cases. As patients admitted multiple times cannot be
identified in the data base, we considered different
interventions to be independent.
The proportion of DES compared to all implanted
stents is shown for men and women in categories of
relevant factors. The 95%-intervals of odds ratios
adjusted standard errors were calculated using the Taylor
linearization technique to allow for clustering. The use
of DES in categories of age and indication for PCI is
visualised in bar charts and tested for interaction by the
Breslow-Day test.
In order to adjust the effect of gender on the choice of
a drug eluting stent for other determinants, the variables
whose distributions differed significantly between men
and women on the one hand and DES and BMS on the
other hand as well as the significant interaction of age
and gender were included in a multivariable logistic
model. As multiple stents implanted during the same ses-
sion strongly tended to be of the same type, generalized
estimating equations assuming an exchangeable working
correlation structure were applied and robust standard
errors calculated for the odds ratios. For explanatory
variables with missing information of more than 1%,
conditional means, calculated by a regression on age,
gender and indication for PCI, were used.
All p-values are the results of two-tailed tests. P-values ≤
0.05 were considered significant. The statistical calculations
have been performed using the SAS system release 9.3 on a
personal computer (SAS Institute, Cary, NC, USA).
Results
Patient characteristics
Women were significantly older than men (71.9 vs.
66.7 years) and were more likely to suffer from diabetes
(26.5% vs 20.2%). In contrast, men more often had previ-
ous CABG or PCI (13.0% vs. 8.2% and 34.7% vs. 28.2%),
while there was no difference regarding renal failure
(Table 1).
The presentation with STEMI, NSTEMI or stable
CAD as well as cardiogenic shock and with or without
signs of heart failure, showed statistically significantly
different but numerically similar values between genders.
The same holds true for the lesion characteristics, where
we found more left anterior descending (LAD) lesions
and fewer left circumflex (CX) lesions, stent re-stenosis
and complex lesions in women than in men. The centre
experience in terms of stent implantations performed
per year was comparable for men and women.
Usage of DES from 2005 to 2009
Between 1st quarter 2005 and 4th quarter 2009, the use
of DES increased from 16.0% to 43.9%. After a rapid
increase from 2005 to early 2006, the implantation rate
reached a plateau and decreased thereafter. Beginning
with the 1st quarter 2008, the rate of DES Implantation
steadily increased until the end of the observation
period. For all quarters of a year that have been analysed,
women received lower rates of DES (p < 0.001; Fig. 1).
Stent diameter
Compared to men, women received stents with lower
diameters, with a mean ± standard deviation of 2.94 ±
0.48 mm vs. 3.04 ± 0.53 mm (p < 0.0001) than in men
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(median 3.0 (quartiles 2.5-3.0) mm vs. 3.0 (2.7-3.5) mm,
Fig. 2a). This difference between women and men was
the same for BMS (2.96 ± 0.48 vs. 3.07 ± 0.53 mm re-
spectively (p < 0.0001) (Fig. 2b), and DES, with a mean
of 2.89 ± 0.48 vs. 2.97 ± 0.51 mm (p < 0.0001) (Fig. 2c).
Relative use of DES in women and men according to
indication
All indications for stent implantation show a lower DES
use in women compared to men. While for stable coron-
ary artery disease and NSTEMI there was significant
difference of 4.0 and 2.5% (p < 0.001) respectively, the
use of DES in STEMI showed a trend (p < 0.086) with an
absolute 1% lower use of DES in women (Fig. 3). How-
ever, no significant interaction was detected (p = 0.11).
Age dependent rate of DES use in women and men
For the women under age 50 years and between 50 and
60 years, there was a trend (p = 0.056 and p = 0.066) to a
higher use of DES in women compared to men, with a
difference of 2.7 and 2.6%, respectively. In the age group
between 60 and 70 years, there is a non significant
Table 1 Patient and procedural chracteristics
Variable Women Men P-value OR (95%-CI)
Number of procedures 22946 59358
Patient history:
Age [years] 71.9 (64.8 – 78.3) 66.7 (57.4 – 73.5) <0.001
Diabetes mellitus 26.5% (5868/22154) 20.2% (11537/57209) <0.001 1.43 (1.38–1.48)
Previous CABG 8.2% (1885/22880) 13.0% (7721/59200) <0.001 0.60 (0.57–0.63)
Previous PCI 28.2% (6419/22747) 34.7% (20432/58861) <0.001 0.74 (0.72–0.76)
Renal disease 13.6% (2977/21943) 13.3% (7510/56639) 0.255 1.03 (0.98–1.07)
Presentation:
STEMI 18.2% (4182/22946) 19.3% (11478/59358) <0.001 0.95 (0.91–0.99)
NSTE-ACS 29.3% (6721/22946) 27.6% (16370/59358) 1.07 (1.04–1.11)
Stable CAD 52.5% (12043/22946) 53.1% (31510/59358) 1a
Cardiogenic shock 1.7% (388/22945) 1.5% (894/59355) 0.055 1.12 (0.99–1.27)
Symptoms of HF 5.6% (1296/22945) 5.0% (2952/59355) <0.001 1.14 (1.07–1.22)
Center volume stents/year 1150 ± 613 1156 ± 623 0.364
Target lesions:
RCA 35.0% (8039/22946) 34.5% (20508/59358) 0.190 1.02 (0.99–1.05)
LAD 45.9% (10526/22946) 41.0% (24358/59358) <0.001 1.22 (1.18–1.26)
CX 23.6% (5412/22946) 26.9% (15972/59358) <0.001 0.84 (0.81–0.87)
Left main stem 2.2% (504/22946) 2.6% (1538/59358) 0.001 0.84 (0.76–0.93)
Bypass graft 1.8% (416/22946) 3.5% (2107/593258) <0.001 0.50 (0.45–0.56)
Implanted stents per PCI 1.40 ± 0.75 1.42 ± 0.76 <0.001
In-stent restenosis 6.5% (1499/22914) 7.3% (4300/59293) <0.001 0.90 (0.84–0.95)
Complex stenosis (≥ B2) 66.6% (15032/22579) 68.3% (39860/58402) <0.001 0.93 (0.90–0.96)
(CABG Coronary artery bypass grafting, PCI percutaneous coronary intervention, CAD coronary artery disease, RCA right coronary artery, LAD left anterior descending
artery, CX left circumflex artery, PCI percutaneous coronary intervention, HF heart failure)
aReference category
Fig. 1 Percentage of DES use in women and men between 1st quarter
2005 (Q1) until 4th quarter 2009 (Q4)
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difference of 0.7%, while women between 70 and 80 years
and over 80 years receive fewer DES compared to men,
2.8% (p < 0.001) and 4.6% (p < 0.001) respectively. The
age group over 70 years comprises over 42% of the stent
implantations that were analysed (Fig. 4). The inter-
action was highly significant (p < 0.0001).
Variables correlating with use of DES
In both genders, heart failure and renal disease are
related to the predominant use of BMS instead of DES
(Table 2), while diabetes and previous PCI or CABG
were associated with a higher use of DES. Concerning
the treated lesions, in-stent restenosis and complex
anatomy as well as left main stem or LAD locations
correlated with greater DES use.
In the multivariable model, diabetes was a strong
predictor of DES use (OR 1.39, p < 0.001), while STEMI
(OR 0.34, p < 0.001), cardiogenic shock (OR 0.56, p <
0.001), NSTEMI-ACS (OR 0.61, p < 0.001), stent
diameter (OR 0.67 for every mm increase in stent diam-
eter, p < 0.001) and age (OR 0.80 for every 10 years
increase in age) and female gender (above the age of 75)
were all associated with a lower usage of DES. As a signifi-
cant interaction between age and gender has been de-
tected (p < 0.0001), the effect estimates of age are reported
Fig. 2 Box plots of stent diameter. Overall stent diameter (a) was
larger in men than in women, as was stent diameter of BMS (b) and
DES(c). Furthermore, overall DES diameter was smaller compared
to BMS
Fig. 3 Relative amount of DES implantation rates in women and
men for different age groups
Fig. 4 Percentage of DES use in stable CAD, NSTEMI- and STEMI-ACS
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separately for men and women, and those of female
gender for distinct age values (Table 3). When we fitted
the regression model separately in the subgroups of stable
CAD, NSTE-ACS and STEMI, the adjusted effect of
female gender on the use of DES was strongest in patients
with stable CAD (OR 0.88 (0.82-0.94) at age 80 years),
weaker in NSTE-ACS (OR 0.90 (0.80-0.99)) and insignifi-
cant in STEMI (OR 1.00 (0.85-1.18)).
Adjuvant medical therapy, major adverse cardiac and
cerebrovascular event (MACCE) and access site
complications
Medical therapy including platelet inhibition and antic-
oagulation in patients aged 70 years and older did not
show a clinically relevant difference between women and
men. However, in-hospital mortality and MACCE were
significantly higher in women. Most notably, the differ-
ence was driven by a significant difference in stable
CAD (Table 4). Non-MACCE related access site compli-
cations, predominantly bleeding, were more common in
women than in men; the difference was significant for
all indications (Table 4).
Discussion
The main finding of our analysis is a lower rate of DES
in elderly women, which is not in accordance with
contemporary guidelines on revascularisation [14].
Gender, vessel size and DES use
Correlated with a smaller body surface area [15], women
have smaller diameter coronary arteries than men, which
explains the inferior results in revascularisation proce-
dures, either PCI [5] or CABG [6]. In the ALKK
(Arbeitsgemeinschaft Leitende Kardiologische Kranken-
hausärzte)-PCI registry we found that stents used in
women were smaller than those used in men, either for
BMS and DES (Fig. 2a, b, c). These data indirectly
confirm, that women have smaller epicardial vessels. For
both genders, DES were more frequently used in smaller
vessels, which reflects the fact that our data were derived
from 2005 to 2009, before large data on the use of DES
in larger vessels were available [16, 17]. The tendency to
use DES in smaller vessels suggests women may receive
a predominance of DES compared to men. However,
univariate analysis showed that women received a lower
percentage of DES compared to men between 2005 and
2009 (Fig. 1). Further analysis in a multivariable logistic
model revealed that the lower likelihood for women to
receive a DES is observed only in women above the age
of 75 year.
The finding of less frequent DES use in women were
also evident irrespective of different indications for PCI,
like stable angina, NSTEMI and STEMI. However, while
the difference in the two former were statistically signifi-
cant, there was only a trend towards a lower usage of DES
in the latter (Fig. 3). The higher frequency of DES
Table 2 Use of DES in women and men
Variable Women Men
DES [%] OR (95%-CI) DES [%] OR (95%-CI)
Total stents 28.2% (7857/27891) 31.3% (22779/72813)
Patient history:
Previous PCI yes/no 43.9/22.3 2.74 (2.56–2.93) 44.7/24.5 2.49 (2.39–2.59)
Previous CABG yes/no 36.3/27.5 1.50 (1.35–1.67) 38.2/30.3 1.42 (1.35–1.50)
Diabetes mellitus yes/no 32.6/26.6 1.34 (1.25–1.43) 36.3/30.3 1.31 (1.25–1.37)
Renal disease yes/no 23.7/29.5 0.74 (0.67–0.82) 28.6/32.5 0.83 (0.78–0.88)
Cardiogenic shock yes/no 9.6/28.5 0.27 (0.18-0.38) 13.7/31.6 0.34 (0.28-0.42)
Symptoms of HF yes/no 16.8/28.9 0.50 (0.42-0.59) 21.3/31.8 0.58 (0.53-0.64)
Lesion characteristics:
RCA 24.9 1* 26.9 1*
LAD 31.8 1.41 (1.32-1.51) 35.8 1.51 (1.45-1.58)
CX 24.2 0.96 (0.89-1.04) 28.9 1.10 (1.05-1.15)
LMCA 45.9 2.56 (2.13-3.08) 50.1 2.73 (2.45-3.03)
Bypass graft 31.2 1.37 (1.12-1.67) 30.0 1.16 (1.06-1.27)
In-stent restenosis yes/no 76.6/25.4 9.62 (8.45-10.95) 75.0/28.5 7.55 (7.00-8.14)
Complex stenosis (≥ B2) 30.9/23.8 1.43 (1.34-1.52) 33.6/27.4 1.34 (1.29-1.39)
All comparisions vs. RCA (as reference), except for CX in woman were sigificant (p<0,05). (CABG coronary artery bypass grafting, PCI percutaneous coronary
intervention, CAD coronary artery disease, RCA right coronary artery, LAD left anterior descending artery, CX left circumflex artery, PCI percutaneous coronary
intervention, HF heart failure, LMCA left main coronary artery)
*Reference category
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implantation in stable disease compared to ACS reflects
data progression suggesting superiority of DES even in
STEMI-ACS [18]. This benefit of DES use in ACS is
confined to reduced repeat target revascularisation,
rather than lower mortality [19].
Explanations for the lower use of DES in elderly women
The underuse of DES is an unexpected finding with
different possible explanations:
First, the lower rates of DES in older women could be
a chance finding. However, the large number of stent
implantations and the high significance (p < 0,001) ren-
der this explanation unlikely. Furthermore, the adjusted
effects show a higher usage of DES in diabetes, whereas
ACS and cardiogenic shock were correlated with a lesser
use of DES (Table 1). These results are all quite expected
and confirm the plausibility of the database.
Another explanation could be an unknown con-
founder accounting for the findings. Concerns exist
regarding DES (and hence dual antiplatelet therapy) use
where there is the need for oral anticoagulation, (such as
after implantation of a mechanical heart valve or as a
result of repeated thrombo-embolic disease). A com-
monly encountered scenario is dual antiplatelet therapy
(DAPT) in addition to oral anticoagulation for patients
with atrial fibrillation. The burden of atrial fibrillation is
unlikely to explain the disparity in DES use in women
Table 3 ALKK PCI-registry 2005-2009: Adjusted effects for the
usage of DES in all stent implantations (n = 29374/97491)
Explanatory variable P value Adjusted
odds ratio
95%-CI
Age [10-year increase] in men <0.001 0.81 0.79-0.82
Age [10-year increase] in women <0.001 0.74 0.72-0.76
Female sex at age 75 years 0.002 0.93 0.89-0.97
Female sex at age 80 years <0.001 0.89 0.84-0.94
Diabetes <0.001 1.29 1.24-1.35
STEMI vs. elective <0.001 0.37 0.36-0.39
NSTEMI vs. elective <0.001 0.64 0.61-0.66
Cardiogenic Shock <0.001 0.46 0.38-0.55
Moderate symptoms of HF <0.001 0.72 0.66-0.80
Previous PCI <0.001 1.80 1.74-1.87
Previous CABG <0.001 1.27 1.21-1.34
LAD <0.001 1.63 1.57-1.68
Left main stem <0.001 2.66 2.41-2.93
In-stent restenosis <0.001 5.63 5.28-6.01
Complex stenosis (≥ B2) <0.001 1.54 1.49-1.60
Stent diameter [for every mm] <0.001 0.81 0.79-0.84
(CABG Coronary artery bypass grafting, PCI percutaneous coronary intervention,
CAD coronary artery disease, RCA right coronary artery, LAD left anterior
descending artery, CX left circumflex artery, PCI percutaneous coronary
intervention, HF heart failure, STEMI ST-elevation myocardial infarction,
NSTEMI non ST-elevation myocardial Infarction)
Table 4 Adjuvant medical therapy, MACCE and access site
complications in women and men ≥ 70 years
Women Men P-value
Medical therapy during PCI
Heparin (%) Total 85.5 84.8 0.160
STEMI 90.7 91.0 0.710
NSTEMI 85.2 84.0 0.184
stable CAD 83.8 83.4 0.606
LMW-Heparin (%) Total 3.4 3.7 0.211
STEMI 4.9 4.4 0.461
NSTEMI 5.7 6.7 0.080
stable CAD 1.5 1.9 0.065
Bivalirudin (%) Total 0.5 0.6 0.281
STEMI 0.4 0.4 0.730
NSTEMI 0.9 0.8 0.893
stable CAD 0.4 0.6 0.113
ASA i.v. (%) Total 43.9 41.6 <0.001
STEMI 66.0 67.1 0.434
NSTEMI 42.1 39.3 0.025
stable CAD 36.9 35.4 0.093
ASA oral (%) Total 62.2 63.7 0.019
STEMI 46.1 47.7 0.313
NSTEMI 65.0 65.2 0.834
stable CAD 66.3 67.5 0.169
Clopidogrel (%) Total 88.5 88.4 0.880
STEMI 91.7 92.1 0.678
NSTEMI 90.8 90.6 0.832
stable CAD 86.0 86.3 0.647
GPIIb/IIIa-Inhibitor (%) Total 21.8 21.5 0.645
STEMI 57.4 59.7 0.085
NSTEMI 26.1 27.3 0.171
stable CAD 7.1 8.3 0.002
Procedure related mortality and MACCE
Mortality (intrahospital) (%) Total 2.8 2.2 0.006
STEMI 9.4 8.4 0.251
NSTEMI 2.9 2.7 0.686
stable CAD 0.6 0.3 0.013
MACCE (Death, MI, Stroke/TIA) (%) Total 3.3 2.8 0.023
STEMI 10.2 9.3 0.399
NSTEMI 3.5 3.2 0.452
stable CAD 1.2 0.8 0.031
Non-MACCE access site related
complications (i.e. bleeding) (%)
Total 3.6 1.8 <0.001
STEMI 4.2 1.3 <0.001
NSTEMI 4.0 2.1 <0.001
stable CAD 3.3 1.8 <0.001
(ASA acetylsalicylic acid, LMW low molecular weight, CABG Coronary artery
bypass grafting, PCI percutaneous coronary intervention, CAD coronary artery
disease, STEMI ST-elevation myocardial infarction, NSTEMI non ST-elevation
myocardial Infarction, MACCE major adverse cardiac and cerebrovascular event)
Significant values are presented in bold
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over 75 compared to men over 75 however because al-
though information about long term anticoagulation or
about atrial fibrillation are not available in our database,
the Framingham heart study [20] suggests atrial fibrilla-
tion is 1.5 times more common in men over 75 compared
to women over 75 so this in itself is unlikely to explain
lower DES use in women of this age. Operators may attri-
bute a higher risk of bleeding to elderly women, which is
based on objective data on higher peri-procedural bleed-
ing complications [21] and a higher prevalence of anemia
[22], that are also predictors of long term mortality [23],
as well as a subjective perception of frailty in elderly
women.
Therefore, even if peri-procedural bleeding complica-
tions do not differ depending on the stent used, the
awareness of a higher liability for bleeding could have
encouraged interventionalists to rather use BMS instead
of DES, whenever there is a suspected risk of bleeding
complications, which is typically encountered in elderly
women. Interestingly, the tendency to use BMS instead of
DES is confined to the type of stent, since anti-platelet
therapy and anticoagulation do not differ (Table 4).
Especially the use of GPIIb/IIIa inhibitors, which are
known for a higher rate of periprocedural bleeding com-
plications [24] (Table 4), was similar in both genders.
Actually, our study (Table 4) confirms a substantially
higher periprocedural risk of access site complication,
bleeding, MACCE and death in women [15, 25, 26].
Given the higher probability of target lesion revasculari-
sations for in stent restenoses with
BMS [27], elderly women are likely exposed to a higher
overall risk due to repeat revascularisation procedures.
Paradoxically, the intention to prevent bleeding
complications in women by the use of BMS instead of
DES, could actually increase morbidity and mortality.
There could be doubts regarding the efficacy of DES
in women, (as women are thought to have less complex
coronary lesions [28] which could be treated equally with
BMS or DES), particularly as DES are more expensive
than BMS. Indeed, Our data shows, a lower percentage of
complex lesions and in-stent restenosis in women
comared to men. While there is a lack of improvement for
mortality and MI, adequately powered RCTs impressively
demonstrated a reduction of target vessel revascularisation
with DES compared to BMS, which were similar for both
sexes [28], even in the elderly [29]. These results were
confirmed by registry data on the use of DES, that
show that these findings proved to be valid in daily
practice [30].
The data from the PCI registry show, that women
receive lower percentage of DES compared to men; this
difference is significant only for the age groups over
70 years (Fig. 4). However, the age group between 70
and 80 years is the largest in the registry and overall,
people older than 70 years account for more than 40%
of the sample. Given the high number of PCIs analysed,
these data are considered to be clinically relevant, show-
ing that women do not receive best available treatment
for coronary artery disease.
Duration of dual anti-platelet therapy
The duration of DAPT was not included in our database,
however, according to guidelines, patients with STEMI
and NSTEMI received DAPT for 12 month, independent
of stent type, while patients with stable CAD received
DAPT for one or six month for BMS and DES, respect-
ively. Actually, we found the biggest difference in stent
usage in the group with stable angina. Given there are
more bleedings, this could explain the tendency to prefer
BMS in elderly woman in the era of 1st generation DES.
However, latest data for 2nd generation DES show
good results for short DAPT, favouring a DAPT for only
three month [31] in patients with concerns of bleeding.
This shortening of DAPT should further reduce the dif-
ference in DES use between men and women.
Limitations
Our large sample, which is representative for current PCI-
procedures in Germany provides data on the use of DES
and BMS in women and men in different revascularisation
settings. However, our study has some limitations.
First, whilst we adjusted for baseline differences, we
cannot fully eliminate them. As a result, it is possible that
unmeasured confounders (especially atrial fibrillation and
oral anticoagulation therapy requirement) exist and may
have contributed to the differences observed. Second, the
analysis that was performed is retrospective and is, there-
fore, dependent on the data already collected.
Conclusion
The ALKK-PCI database shows a distinctly lower use of
DES in elderly women. This difference is not supported by
guidelines or recent published trials. As undertreatment
cannot be studied by randomised controlled trials, other
available databases on PCI should be analysed for gender
differences in DES implantation.
More effort should be made to uniformly implement
of current revascularisation guidelines across groups,
thereby eliminating gender differences in care.
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